HCV_M&A - “Mirror, Mirror on the Wall (HCV) – Who is the Fairest of them all!”
2011 proved to be a bonanza for companies focused in HCV especially after the acquisition of Pharmasset (VRUS) by Gilead (GILD), Anadys by Roche and stellar launch of INCIVEK by vertex. With the announcement by Bristol-Myers Squibb (BMY) to acquire Inhibitex (INHX), 2012 also is likely to be an important year for HCV therapy class. Key data is expected which will decide the winner(s) in the race for “an all oral” option (IFN Free) for Treatment of HCV. Who is going to be next? Achillion (ACHN), Idenix (IDIX), Idera (IDRA), Santaris (Pvt.), and GlobeImmune (Pvt.) etc. Vertex, the current leader in HCV hedges the risk. For more details, please read our report released on 10th January, 2012 on HCV_M&A titled “Mirror, Mirror on the Wall (HCV) – Who is the Fairest of them all!”
COMPANIES MENTIONED
GILEAD, VERTEX, BRISTOL MYERS,
GILEAD, VERTEX, BRISTOL MYERS,
